Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
ANIK
#2995
Anika Therapeutics Inc
14.360
0
+14.42%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+14.42%
Variazione Mensile
+55.50%
Variazione di 6 mesi
+41.62%
Variazione Annuale
+41.62%
Chiusura Precedente
12.550
0
Open
14.360
0
Bid
Ask
Low
14.360
0
High
14.360
0
Volume
44
Mercati
Mercato Azionario Statunitense
Salute
ANIK
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
14.33 M
14.47 M
14.63 M
14.85 M
14.18 M
—
Valuation ratios
Enterprise value
552.74 M
423.97 M
345.05 M
263.63 M
177.71 M
516.83 M
Price to earnings ratio
-26.78
127.96
-28.9
-4.02
-4.3
-14.88
Price to sales ratio
4.93
3.55
2.75
1.99
2.02
6.08
Price to cash flow ratio
49.27
62.44
97.36
185.74
44.85
137.02
Price to book ratio
2.36
1.83
1.5
1.56
1.57
2.37
Enterprise value to EBITDA ratio
-9.28
-41.24
-28.67
-3.36
-29.24
-41.01
Profitability ratios
Return on assets %
0.07
0.01
0.04
0.31
0.28
0.17
Return on equity %
0.09
0.01
0.05
0.39
0.37
0.22
Return on invested capital %
50.18
1.3
28.3
200.62
-20.05
49.65
Gross margin %
52.91
56.12
59.89
61.85
63.38
218.99
Operating margin %
21.71
1.77
12.42
52.58
4.25
45.11
EBITDA margin %
-45.63
-6.96
-7.7
-47.08
-5.07
-51.21
Net margin %
18.38
2.8
9.51
49.6
47.02
112.51
Liquidity ratios
Quick ratio
3.56
4.45
4.65
3.76
3.85
17.98
Current ratio
4.81
5.66
6.07
5.26
4.88
22.1
Inventory turnover
1.8
1.58
1.65
1.48
1.25
2.39
Asset turnover
0.37
0.41
0.45
0.54
0.51
0.57
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.92
0.57
0.3
0.12
0.37
0.56
EBIT per share
-5.15
-1.69
-1.83
-6.32
-0.8
-1.42
EBITDA per share
-4.19
-0.7
-0.83
-5.35
-0.41
-0.99
Total debt per share
—
—
—
—
—
—
Cash per share
6.91
6.45
8.31
7.43
5.38
21.53
Net current asset value per share
12.47
11.52
11.64
11.14
7.72
28.78
Tangible book value per share
12.15
13.46
13.98
13.65
9.81
38.52
Working capital per share
9.88
9.48
9.73
9.02
6.14
23.51
Book value per share
19.15
19.62
19.61
14.48
10.46
41.19
Notizie
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika Q4 2025: l’impennata commerciale compensa il calo OEM
Anika Q4 2025 slides: commercial surge offsets OEM decline
Anika earnings beat by $0.45, revenue topped estimates
Lumicell appoints Cheryl Blanchard to board of directors
Anika Therapeutics names Stephen Griffin as new CEO
Slide di Anika del Q3 2025: La crescita commerciale compensa il calo OEM
Anika Q3 2025 slides: Commercial growth offsets OEM decline
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika earnings beat by $0.22, revenue was in line with estimates
Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?
Wall Street Analysts See a 98.59% Upside in Anika (ANIK): Can the Stock Really Move This High?